Revenue
No reported data
Apimeds Pharmaceuticals US, Inc. (APUS)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Research & development | $1.6M | — | $98,544 |
| Operating expenses | $11.9M | $1.3M | — |
| Operating income | −$11.9M | −$1.3M | −$747,436 |
| Net income | −$6.0M | −$1.4M | −$777,694 |
| Basic EPSper diluted share | -$0.55 | -$0.18 | -$0.17 |
| Diluted EPSper diluted share | -$0.55 | -$0.18 | -$0.17 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 14, 2025Form 4 | Kim ChristopherChairman and CMO | BuyCommon Stock, par value $0.01 per share | 7.7K | $1.86 | $14.4K | 27.5K |
| May 13, 2025Form 4 | Kim ChristopherChairman and CMO | BuyCommon Stock, par value $0.01 per share | 19.8K | $1.82 | $36.0K | 19.8K |
| May 12, 2025Form 4 | Koo JakapDirector | BuyCommon Stock, par value $0.01 per share | 28.5K | $1.99 | $56.7K | 643.9K |
| May 12, 2025Form 4 | Inscobee Inc.TenPercentOwner | BuyCommon Stock, par value $0.01 per share | 500.0K | $4.00 | $2.00M | 1.98M |